11814 COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY

posed Government pricing policy. In his quote which we used he wasn't talking about pricing policy. He was stating his views on the scientific issue.

Mr. Gordon. Well, he says here—the bioequivalence has not rele-

vancy. But you are relating it here to a pricing policy?

Mr. Stetler. I am relating it in this section of the report to a discussion of the issue of bioequivalency.

Mr. Gordon. That is right. And you are discussing bioequivalency as it relates to a pricing policy.

Mr. Stetler. No doubt about it.

Mr. Gordon. But your quotation of Dr. Edwards does not reflect Dr. Edwards' later thinking.

Mr. Stetler. I didn't think he had changed his mind on the specific

Mr. Gordon. I am just calling that to your attention, because it is inaccurate, I think, to use an early statement when the same person has subsequently changed his mind.

Mr. Stetler. You have to look at the circumstances under which

he made his statement, too.

The CHAIRMAN. Thank you very much, gentlemen. I appreciate

your taking the time to come up.
[Whereupon, at 1:10 p.m., the subcommittee adjourned, subject to the call of the Chair.]